

## Key Figures of Consolidated Financial Results for 1st Quarter FY2025

August 1st, 2025  
Sumitomo Chemical Co., Ltd.  
(Billions of yen)

### 1. Financial Summary (IFRS)

	Q1 FY2025	Q1 FY2024	Variance	FY2025 (Forecast)	FY2024
Sales revenue	526.1	612.1	(86.0)	2,340.0	2,606.3
Core operating income	27.7	5.7	22.0	150.0	140.5
Operating income	25.5	11.5	14.0	105.0	193.0
Net income (loss) attributable to owners of the parent	(4.5)	24.4	(28.9)	40.0	38.6
Basic earnings (loss) per share	¥ (2.76)	¥ 14.91	¥ (17.67)	¥ 24.44	¥23.59
Return on equity	(0.5)%	2.5%	(3.0)%	4.2%	4.1%
Exchange rate (yen/\$)	144.59	155.85	—	145.00	152.62
Naphtha price (yen/kl)	65,500	79,000	—	68,000	75,600

\*Core operating income is a gain and loss concept that reflects recurring earning capacity by deducting gains and losses incurred by non-recurring factors from operating income, which includes the share of profits or losses from investments accounted for using the equity method.

### 2. Sales Revenue / Core Operating Income by Reportable Segment (IFRS)

(Billions of yen)

		Q1 FY2025	Q1 FY2024	Variance	FY2025 (Forecast)	FY2024
Agro & Life Solutions	Sales revenue	96.9	106.4	(9.5)	530.0	540.2
	Core operating income	2.2	4.9	(2.7)	55.0	55.0
ICT & Mobility Solutions	Sales revenue	137.4	152.7	(15.3)	580.0	607.0
	Core operating income	18.4	21.2	(2.8)	56.0	70.6
Advanced Medical Solutions	Sales revenue	9.1	13.2	(4.1)	60.0	62.1
	Core operating income	(1.0)	0.5	(1.5)	4.0	4.0
Essential & Green Materials	Sales revenue	165.4	225.0	(59.6)	780.0	899.0
	Core operating income	(5.5)	(19.6)	14.1	(10.0)	(58.5)
Sumitomo Pharma	Sales revenue	107.4	90.6	16.8	350.0	398.0
	Core operating income	21.0	0.9	20.1	59.0	35.3
Others	Sales revenue	10.0	24.3	(14.3)	40.0	99.9
	Core operating income	1.8	4.9	(3.2)	16.0	66.9
Adjustments	Sales revenue	—	—	—	—	—
	Core operating income	(9.2)	(7.1)	(2.0)	(30.0)	(32.7)
Total	Sales revenue	526.1	612.1	(86.0)	2,340.0	2,606.3
	Core operating income	27.7	5.7	22.0	150.0	140.5

\*The Group changed its reportable segments from Q3 FY2024. The segment information for 1Q FY2024 has been reclassified to reflect the change in the reportable segments.

### 3. Summary of Consolidated Statement of Income (IFRS)

(Billions of yen)

	Q1 FY2025	Q1 FY2024	Variance	Variance Ratio
Sales revenue	526.1	612.1	(86.0)	(14.0)%
Core operating income	27.7	5.7	22.0	388.2%
Of which equity in earnings	(9.8)	(17.4)	7.5	—
Total non-recurring items	(2.2)	5.8	(8.1)	—
Of which restructuring costs	(2.7)	(3.5)	0.8	—
Of which gains on sales of property, plant and equipment, and intangible assets	0.1	10.1	(10.0)	—
Others	0.4	(0.8)	1.1	—
Operating income	25.5	11.5	14.0	121.3%
Finance income/expenses	(19.6)	26.0	(45.6)	—
Of which gain (loss) on foreign currency transactions including gain (loss) on derivatives	(16.4)	29.0	(45.4)	—
Others	(3.3)	(3.0)	(0.2)	—
Income before taxes	5.8	37.5	(31.7)	(84.5)%
Income tax expenses	(1.9)	(3.6)	1.7	—
Net income	3.9	33.9	(30.0)	(88.6)%
Net loss attributable to non-controlling interests	(8.4)	(9.5)	1.1	—
Net income (loss) attributable to owners of the parent	(4.5)	24.4	(28.9)	—
ROE	(0.5)%	2.5%		
Exchange rate (yen/\$)	144.59	155.85		
Naphtha price (yen/kl)	65,500	79,000		
Overseas sales revenue ratio	68.5%	69.2%		

### 4. Summary of Consolidated Statement of Financial Position (IFRS)

(Billions of yen)

	30-June-25	31-Mar-25	Variance		30-June-25	31-Mar-25	Variance
Current Assets	1,500.5	1,583.1	(82.6)	Liabilities	2,268.2	2,365.4	(97.2)
Cash and cash equivalents	142.6	209.8	(67.3)	Trade and other payables	479.2	488.1	(9.0)
Trade and other receivables	538.9	593.8	(54.9)	Interest-bearing liabilities	1,248.1	1,286.1	(38.0)
Inventories	646.5	625.2	21.3	Others	540.9	591.1	(50.2)
Others	172.4	154.2	18.2	Equity	1,061.4	1,074.4	(13.0)
Non-current assets	1,829.1	1,856.7	(27.6)	Shareholders' equity	709.8	722.3	(12.5)
Property, plant and equipment	755.9	759.3	(3.4)	Other components of equity	176.1	178.5	(2.4)
Goodwill and intangible assets	480.1	497.1	(17.0)	Non-controlling interests	175.5	173.6	1.9
Others	593.1	600.3	(7.1)				
Total	3,329.5	3,439.8	(110.2)	Total	3,329.5	3,439.8	(110.2)
				Ratio of equity attributable to owners of the parent to total assets	26.6%	26.2%	0.4%
				D/E ratio (times)	1.18	1.20	(0.02)

5. Summary of Consolidated Statement of Cash Flows (IFRS)

	Q1 FY2025	Q1 FY2024	Variance	(Billions of yen) FY2024
Cash flows from operating activities	24.0	(12.3)	36.3	233.0
Cash flows from investing activities	(45.9)	82.5	(128.4)	85.2
Free cash flows	(21.9)	70.2	(92.2)	318.3
Cash flows from financing activities	(49.2)	(63.0)	13.8	(300.8)
Others	(0.9)	6.9	(7.7)	(6.8)
Increase (decrease) in cash and cash equivalents	(72.1)	14.1	(86.1)	10.7
Cash and cash equivalents at the end of the period	142.6	234.3	(91.7)	209.8

Note: This document has been translated from the Japanese-language original (hereinafter, the "original") for reference purposes only. In the event of any discrepancy between this translated document and the original, the original shall prevail. The original of Quarterly Consolidated Financial Statements has undergone a review by the Company's audit firm. Please refer to the Japanese review report for details.



August 1, 2025

## Summary of Consolidated Financial Results for First Quarter Fiscal Year 2025 (Under IFRS)

Company name: Sumitomo Chemical Co., Ltd.  
 Listing: Tokyo Stock Exchange  
 Securities code: 4005  
 URL: <https://www.sumitomo-chem.co.jp/english/>  
 Representative: Nobuaki Mito, Representative Director & President  
 Inquiries: Shunji Kobayashi, General Manager, Corporate Communications Dept.  
 Telephone: +81-3-5201-0200  
 Scheduled date to commence dividend payments: —  
 Preparation of supplementary material on financial results: Yes  
 Holding of financial results briefing: Yes (for institutional investors and analysts)

(All amounts are rounded to the nearest million yen.)

### 1. Consolidated Financial Results for First Quarter Fiscal Year 2025 (April 1, 2025 to June 30, 2025)

#### (1) Consolidated Operating Results

(Percentages indicate year-on-year changes.)

	Sales revenue		Core operating income		Operating income		Net income		Net income attributable to owners of the parent		Total comprehensive income	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Q1 FY2025	526,140	(14.0)	27,681	388.2	25,452	121.3	3,873	(88.6)	(4,523)	—	1,125	(98.4)
Q1 FY2024	612,144	8.7	5,670	—	11,499	—	33,886	—	24,383	—	69,876	(6.2)

	Basic earnings per share	Diluted earnings per share
	Yen	Yen
Q1 FY2025	(2.76)	—
Q1 FY2024	14.91	14.90

Reference: Share of profit or loss of investments accounted for using the equity method

Q1 FY2025: ¥ (9,826) million    Q1 FY2024: ¥ (17,352) million

Income before taxes

Q1 FY2025: ¥ 5,817 million    Q1 FY2024: ¥ 37,481 million

\*Core operating income is a gain and loss concept that reflects recurring earning capacity by deducting gains and losses incurred by non-recurring factors from operating income, which includes the share of profits or losses from investments accounted for using the equity method.

\*For diluted earnings per share for Q1 FY2025, although there are potential shares, they are not listed because they have an anti-dilutive effect.

#### (2) Consolidated Financial Position

	Total assets	Total equity	Equity attributable to owners of the parent	Ratio of equity attributable to owners of the parent to total assets
As of	Millions of yen	Millions of yen	Millions of yen	%
June 30, 2025	3,329,549	1,061,390	885,865	26.6
March 31, 2025	3,439,784	1,074,415	900,790	26.2

## 2. Dividends

	Dividends per share				
	1st quarter end	2nd quarter end	3rd quarter end	Year-end	Annual
	Yen	Yen	Yen	Yen	Yen
FY2024	—	3.00	—	6.00	9.00
FY2025	—				
FY2025 (Forecast)		6.00	—	6.00	12.00

Note: Revision of dividend forecasts from the latest announcement: None

## 3. Consolidated Financial Forecasts for Fiscal Year 2025

(April 1, 2025 to March 31, 2026)

(Percentages indicate year-on-year changes.)

	Sales revenue		Core operating income		Operating income		Net income attributable to owners of the parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
First-half of FY2025	1,100,000	(11.4)	90,000	205.3	85,000	(29.9)	25,000	—	15.28
Full-year of FY2025	2,340,000	(10.2)	150,000	6.7	105,000	(45.6)	40,000	3.7	24.44

Note: Revision of financial forecasts from the latest announcement: None

We now announce the consolidated financial forecast for the first-half of FY2025 as above, which was not announced in the "Summary of Consolidated Financial Results for Fiscal Year 2024 (Under IFRS)" disclosed on May 14, 2025. There are no changes to the consolidated financial forecast for FY2025.

### Notes:

(1) Significant changes in the scope of consolidation during the period: Yes

Newly included: —

Excluded: 1 company (XUYOU Electronic Materials (Wuxi) Co., Ltd.)

(2) Changes in accounting policies and changes in accounting estimates

- (i) Changes in accounting policies required by IFRS: None
- (ii) Changes in accounting policies due to other reasons: None
- (iii) Changes in accounting estimates: None

(3) Number of shares issued (common shares)

(i) Total number of shares issued at the end of the period (including treasury shares)

As of June 30, 2025	1,657,217,608 shares
As of March 31, 2025	1,657,217,608 shares

(ii) Number of treasury shares at the end of the period

As of June 30, 2025	20,519,186 shares
As of March 31, 2025	20,517,033 shares

(iii) Average number of shares outstanding during the period

Three Months ended June 30, 2025	1,636,496,435 shares
Three Months ended June 30, 2024	1,635,748,188 shares

\*Review of the Japanese-language original of the attached quarterly consolidated financial statements by certified public accountants or an audit firm: Yes (voluntary)

\*Notes to appropriate use of forecasts and other special items:

Descriptions regarding forward-looking statements about the future performance of the Company contained in this summary are based on information currently available to the Company and certain assumptions judged reasonable and involve risks and uncertainties. The important factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, general economic conditions in the Company's markets; demand for, and competitive pricing pressure on, the Company's products in the marketplace; rise in prices of raw materials; and fluctuations in foreign exchange rates.

## Attachments

1. Summary of Operating Results for First Quarter Fiscal Year 2025 .....	2
(1) Operating Results .....	2
(2) Consolidated Financial Position .....	3
(3) Consolidated Forecast and Other Forward-Looking Information .....	3
2. Consolidated Financial Statements and Major Notes .....	4
(1) Consolidated Statement of Financial Position .....	4
(2) Consolidated Statement of Income and Consolidated Statement of Comprehensive Income .....	6
(3) Consolidated Statement of Changes in Equity .....	8
(4) Consolidated Statement of Cash Flows .....	10
(5) Notes to Consolidated Financial Statements .....	11
(Framework of Financial Report) .....	11
(Going Concern Assumption) .....	11
(Segment Information) .....	11
(Material Subsequent Events) .....	13

## 1. Summary of Operating Results for First Quarter Fiscal Year 2025

### (1) Operating Results

For Q1 FY2025, the Group's sales revenue decreased by ¥86.0 billion compared to Q1 FY2024, to ¥526.1 billion. In terms of profits and losses, core operating income\* was ¥27.7 billion, and operating income was ¥25.5 billion, both higher than in Q1 FY2024. Net income attributable to owners of the parent was a loss of ¥4.5 billion, lower than in Q1 FY2024.

\*Core operating income is a gain and loss concept that reflects recurring earning capacity by deducting gains and losses incurred by non-recurring factors from operating income, which includes the share of profits or losses from investments accounted for using the equity method.

The financial results by reportable segment for Q1 FY2025 are as follows:

#### Agro & Life Solutions

Shipments of crop protection products in India and elsewhere were strong. However, market conditions for methionine (feed additives) deteriorated compared to Q1 FY2024. The stronger yen also had a negative effect on sales from subsidiaries outside of Japan when converted into yen. As a result, sales revenue decreased by ¥9.5 billion from Q1 FY2024, to ¥96.9 billion. Core operating income was ¥2.2 billion, decreased by ¥2.7 billion from Q1 FY2024.

#### ICT & Mobility Solutions

The stronger yen decreased income from exports and had a negative effect on sales from subsidiaries outside of Japan in yen terms. In addition, shipments of display-related materials declined partly because of the impact of fundamental structural reforms implemented for the polarizing film business for large-size liquid crystal displays, and partly because of consumer sentiment deteriorated over concerns about a potential recession. As a result, sales revenue decreased by ¥15.3 billion from Q1 FY2024, to ¥137.4 billion. Core operating income was ¥18.4 billion, decreased by ¥2.8 billion from Q1 FY2024.

#### Advanced Medical Solutions

Shipments of active pharmaceutical ingredients and intermediates decreased, because the timing of shipments for some products differed from Q1 FY2024. As a result, sales revenue decreased by ¥4.1 billion from Q1 FY2024, to ¥9.1 billion. Core operating income posted a loss of ¥1.0 billion, a decline in income of ¥1.5 billion from Q1 FY2024.

#### Essential & Green Materials

Shipments of the sales subsidiary declined, because of the periodic shutdown maintenance at Rabigh Refining and Petrochemical Company (hereinafter, "Petro Rabigh"), an affiliated company accounted for by the equity method. In addition, shipments of aluminum and others decreased due to the Group's exit from the business in FY2024. As a result, sales revenue decreased by ¥59.6 billion from Q1 FY2024, to ¥165.4 billion. Core operating income posted a loss of ¥5.5 billion, improved by ¥14.1 billion from Q1 FY2024, due to an improvement in the terms of trade for Petro Rabigh and for synthetic resins and others.

#### Sumitomo Pharma

In North America, there was an increase in sales of ORGOVYX® (therapeutic agent for advanced prostate cancer) and GEMTESA® (therapeutic agent for overactive bladder). As a result, sales revenue increased by ¥16.8 billion from Q1 FY2024, to ¥107.4 billion. Core operating income was ¥21.0 billion, increased by ¥20.1 billion from Q1 FY2024, because of increased sales revenue and a significant reduction in selling, general and administrative expenses including research and development expenses resulting from the effects of business structure improvement. Sales revenue and core operating income differ between this segment and Sumitomo Pharma, Co., Ltd., a subsidiary of Sumitomo Chemical Co., Ltd. due to the Group's contract development and manufacturing organization business for regenerative medicine and cell therapy products not being included in this segment and because of the Group's consolidated account reporting.

#### Others

In addition to the above five segments, the Group supplies electric power and steam, and also provides transportation and warehousing. Sales revenue decreased by ¥14.3 billion from Q1 FY2024, to ¥10.0 billion, due to the sale of the radiopharmaceutical business and other businesses in FY2024. Core operating income decreased by ¥3.2 billion from Q1 FY2024, to ¥1.8 billion.

## (2) Consolidated Financial Position

As of the end of Q1 FY2025, total assets decreased by ¥110.2 billion compared to the end of FY2024, to ¥3,329.5 billion. Cash and cash equivalents as well as trade and other receivables decreased.

Total liabilities decreased by ¥97.2 billion compared to the end of FY2024, to ¥2,268.2 billion. Interest-bearing liabilities decreased by ¥38.0 billion compared to the end of FY2024, to ¥1,248.1 billion.

Total equity (including non-controlling interests) decreased by ¥13.0 billion compared to the end of FY2024, to ¥1,061.4 billion, mainly due to the payment of dividends and other factors.

The ratio of equity attributable to the owners of the parent to total assets increased by 0.4 percentage points compared to the end of FY2024, to 26.6%.

## (3) Consolidated Forecast and Other Forward-Looking Information

Based on recent performance trends, the Company announces its previously undisclosed consolidated financial forecast for the first half of FY2025, as detailed below, assuming an average exchange rate of 145.00 yen/US\$ and a naphtha price of 63,800 yen/KL.

The forecast for FY2025 is currently under review and the revised forecast will be explained when the consolidated financial results for the first half of FY2025 is announced.

### Consolidated Financial Forecast for the First Half of FY2025 (April 1, 2025 – September 30, 2025)

(Millions of yen)

	Sales Revenue	Core Operating Income	Operating Income	Net Income Attributable to Owners of the Parent	Earnings per Share (yen)
Previous forecast (A)	TBD	TBD	TBD	TBD	TBD
Revised forecast (B)	1,100,000	90,000	85,000	25,000	15.28
Variance in amount (B-A)	-	-	-	-	
Variance in percentage (%)	-	-	-	-	
Results for the first half of FY2024	1,241,395	29,476	121,249	(6,527)	(3.99)

(Supplemental information)

### Consolidated Financial Forecast by Segment for the First Half of FY2025

(Millions of yen)

		Current forecast	Results for the first half of FY2024
Agro & Life Solutions	Sales revenue	210,000	225,004
	Core operating income	16,000	14,161
ICT & Mobility Solutions	Sales revenue	280,000	307,460
	Core operating income	32,000	43,581
Advanced Medical Solutions	Sales revenue	25,000	26,750
	Core operating income	(1,000)	355
Essential & Green Materials	Sales revenue	360,000	450,932
	Core operating income	(19,000)	(34,759)
Sumitomo Pharma	Sales revenue	205,000	180,400
	Core operating income	72,000	3,040
Others & Adjustments	Sales revenue	20,000	50,849
	Core operating income	(10,000)	3,098
Total	Sales revenue	1,100,000	1,241,395
	Core operating income	90,000	29,476



## 2. Consolidated Financial Statements and Major Notes

### (1) Consolidated Statement of Financial Position

Millions of yen	As of June 30, 2025	As of March 31, 2025
<b>Assets</b>		
Current assets:		
Cash and cash equivalents	¥ 142,561	¥ 209,838
Trade and other receivables	538,949	593,836
Other financial assets	60,091	45,015
Inventories	646,530	625,243
Other current assets	63,330	49,993
Subtotal	1,451,461	1,523,925
Assets held for sale	49,028	59,209
Total current assets	1,500,489	1,583,134
Non-current assets:		
Property, plant and equipment	755,865	759,266
Goodwill	250,508	257,811
Intangible assets	229,581	239,319
Investments accounted for using the equity method	273,510	287,977
Other financial assets	184,162	177,405
Retirement benefit assets	73,331	72,618
Deferred tax assets	36,854	34,608
Other non-current assets	25,249	27,646
Total non-current assets	1,829,060	1,856,650
Total assets	¥ 3,329,549	¥ 3,439,784

**Liabilities and equity****Liabilities**

## Current liabilities:

Bonds and borrowings	¥	218,033	¥	252,892
Trade and other payables		479,168		488,132
Other financial liabilities		73,018		81,364
Income taxes payable		7,201		10,627
Provisions		85,885		89,711
Other current liabilities		88,366		109,360
Subtotal		951,671		1,032,086
Liabilities directly associated with assets held for sale		8,508		6,661
Total current liabilities		960,179		1,038,747
Non-current liabilities:				
Bonds and borrowings		1,030,074		1,033,236
Other financial liabilities		87,900		91,157
Retirement benefit liabilities		23,884		24,841
Provisions		27,703		25,974
Deferred tax liabilities		107,199		111,048
Other non-current liabilities		31,220		40,366
Total non-current liabilities		1,307,980		1,326,622
Total liabilities		2,268,159		2,365,369

**Equity**

Share capital		90,059		90,059
Retained earnings		628,066		640,611
Treasury shares		(8,361)		(8,361)
Other components of equity		173,299		174,871
Other comprehensive income associated with assets held for sale		2,802		3,610
Equity attributable to owners of the parent		885,865		900,790
Non-controlling interests		175,525		173,625
Total equity		1,061,390		1,074,415
Total liabilities and equity	¥	3,329,549	¥	3,439,784

## (2) Consolidated Statement of Income and Consolidated Statement of Comprehensive Income

### Consolidated Statement of Income

First Quarter ended June 30, 2025 and 2024

Millions of yen	Q1 FY2025		Q1 FY2024	
Sales revenue	¥	526,140	¥	612,144
Cost of sales		(362,436)		(440,306)
Gross profit		163,704		171,838
Selling, general and administrative expenses		(133,621)		(151,235)
Other operating income		10,347		13,632
Other operating expenses		(5,152)		(5,384)
Share of profit (loss) of investments accounted for using the equity method		(9,826)		(17,352)
Operating income		25,452		11,499
Finance income		6,681		40,162
Finance expenses		(26,316)		(14,180)
Income before taxes		5,817		37,481
Income tax expenses		(1,944)		(3,595)
Net income		3,873		33,886
Net income (loss) attributable to:				
Owners of the parent		(4,523)		24,383
Non-controlling interests		8,396		9,503
Net income	¥	3,873	¥	33,886

Yen	Q1 FY2025	Q1 FY2024
Earnings per share:		
Basic earnings (loss) per share	(2.76)	14.91
Diluted earnings per share	—	14.90

## Consolidated Statement of Comprehensive Income

First Quarter ended June 30, 2025 and 2024

Millions of yen	Q1 FY2025	Q1 FY2024
Net income	¥ 3,873	¥ 33,886
Other comprehensive income:		
Items that will not be reclassified to profit or loss		
Remeasurements of financial assets (equity instruments) measured at fair value through other comprehensive income	5,464	(5,376)
Remeasurements of defined benefit plans	227	(7)
Share of other comprehensive income of investments accounted for using the equity method	203	981
Total items that will not be reclassified to profit or loss	5,894	(4,402)
Items that may be subsequently reclassified to profit or loss		
Remeasurements of financial assets (debt instruments) measured at fair value through other comprehensive income	23	—
Cash flow hedges	(354)	387
Exchange differences on conversion of foreign operations	149	29,117
Share of other comprehensive income of investments accounted for using the equity method	(8,460)	10,888
Total items that may be subsequently reclassified to profit or loss	(8,642)	40,392
Other comprehensive income, net of taxes	(2,748)	35,990
Total comprehensive income	1,125	69,876
Total comprehensive income attributable to:		
Owners of the parent	(5,105)	62,157
Non-controlling interests	6,230	7,719
Total comprehensive income	¥ 1,125	¥ 69,876

### (3) Consolidated Statement of Changes in Equity

First Quarter ended June 30, 2025

	Equity attributable to owners of the parent						Other components of equity	
	Share capital	Capital surplus	Retained earnings	Treasury shares			Remeasurements of financial assets measured at fair value through other comprehensive income	Remeasurements of defined benefit plans
Millions of yen								
Balance as of April 1, 2025	¥ 90,059	¥ —	¥ 640,611	¥ (8,361)			¥ 1,186	¥ —
Net income (loss)	—	—	(4,523)	—			—	—
Other comprehensive income	—	—	—	—			5,736	224
Total comprehensive income	—	—	(4,523)	—			5,736	224
Purchase of treasury shares	—	—	—	(1)			—	—
Disposal of treasury shares	—	—	(0)	0			—	—
Dividends	—	—	(9,820)	—			—	—
Changes resulting from loss of control of subsidiaries	—	—	1,832	—			(1,611)	(221)
Changes in interest due to transactions with non-controlling interests	—	—	—	—			—	—
Transfer from other components of equity to retained earnings	—	—	(34)	—			37	(3)
Transfer to other comprehensive income associated with assets held for sale	—	—	—	—			—	—
Total transactions with owners	—	—	(8,022)	(1)			(1,574)	(224)
Balance as of June 30, 2025	¥ 90,059	¥ —	¥ 628,066	¥ (8,361)			¥ 5,348	¥ —

	Equity attributable to owners of the parent						Non-controlling interests	Total equity	
	Other components of equity			Other comprehensive income associated with assets held for sale	Equity attributable to owners of the parent				
	Cash flow hedges	Exchange differences on conversion of foreign operations	Total						
Balance as of April 1, 2025	¥	87	¥ 173,598	¥ 174,871	¥	3,610	¥ 900,790	¥ 173,625	¥1,074,415
Net income (loss)		—	—	—		—	(4,523)	8,396	3,873
Other comprehensive income		(364)	(2,890)	2,706		(3,288)	(582)	(2,166)	(2,748)
Total comprehensive income		(364)	(2,890)	2,706		(3,288)	(5,105)	6,230	1,125
Purchase of treasury shares		—	—	—		—	(1)	—	(1)
Disposal of treasury shares		—	—	—		—	0	—	0
Dividends		—	—	—		—	(9,820)	(1,154)	(10,974)
Changes resulting from loss of control of subsidiaries		—	—	(1,832)		—	—	(3,176)	(3,176)
Changes in interest due to transactions with non-controlling interests		—	—	—		—	—	—	—
Transfer from other components of equity to retained earnings		—	—	34		—	—	—	—
Transfer to other comprehensive income associated with assets held for sale		—	(2,480)	(2,480)		2,480	—	—	—
Total transactions with owners		—	(2,480)	(4,278)		2,480	(9,821)	(4,330)	(14,151)
Balance as of June 30, 2025	¥	(277)	¥ 168,228	¥ 173,299	¥	2,802	¥ 885,865	¥ 175,525	¥1,061,390

First Quarter ended June 30, 2024

	Equity attributable to owners of the parent											
	Share capital	Capital surplus	Retained earnings	Treasury shares	Other components of equity							
					Remeasurements of financial assets measured at fair value through other comprehensive income	Remeasurements of defined benefit plans						
Millions of yen												
Balance as of April 1, 2024	¥	89,938	¥	237	¥	578,175	¥	(8,355)	¥	83,448	¥	—
Net income (loss)		—		—		24,383		—		—		—
Other comprehensive income		—		—		—		—		(623)		274
Total comprehensive income		—		—		24,383		—		(623)		274
Purchase of treasury shares		—		—		—		(1)		—		—
Disposal of treasury shares		—		(0)		—		0		—		—
Dividends		—		—		(4,908)		—		—		—
Changes resulting from loss of control of subsidiaries		—		—		—		—		—		—
Changes in interest due to transactions with non-controlling interests		—		(24)		—		—		—		—
Transfer from other components of equity to retained earnings		—		—		27,001		—		(26,727)		(274)
Transfer to other comprehensive income associated with assets held for sale		—		—		—		—		—		—
Total transactions with owners		—		(24)		22,093		(1)		(26,727)		(274)
Balance as of June 30, 2024	¥	89,938	¥	213	¥	624,651	¥	(8,356)	¥	56,098	¥	—

	Equity attributable to owners of the parent						
	Other components of equity			Other comprehensive income associated with assets held for sale	Equity attributable to owners of the parent	Non-controlling interests	Total equity
	Cash flow hedges	Exchange differences on conversion of foreign operations	Total				
Balance as of April 1, 2024	¥ 319	¥ 220,266	¥ 304,033	¥ 1,725	¥ 965,753	¥ 198,613	¥1,164,366
Net income (loss)	—	—	—	—	24,383	9,503	33,886
Other comprehensive income	387	39,461	39,499	(1,725)	37,774	(1,784)	35,990
Total comprehensive income	387	39,461	39,499	(1,725)	62,157	7,719	69,876
Purchase of treasury shares	—	—	—	—	(1)	—	(1)
Disposal of treasury shares	—	—	—	—	0	—	0
Dividends	—	—	—	—	(4,908)	(2,440)	(7,348)
Changes resulting from loss of control of subsidiaries	—	—	—	—	—	28	28
Changes in interest due to transactions with non-controlling interests	—	—	—	—	(24)	24	—
Transfer from other components of equity to retained earnings	—	—	(27,001)	—	—	—	—
Transfer to other comprehensive income associated with assets held for sale	—	118	118	(118)	—	—	—
Total transactions with owners	—	118	(26,883)	(118)	(4,933)	(2,388)	(7,321)
Balance as of June 30, 2024	¥ 706	¥ 259,845	¥ 316,649	¥ (118)	¥1,022,977	¥ 203,944	¥1,226,921

#### (4) Consolidated Statement of Cash Flows

First Quarter ended June 30, 2025 and 2024

Millions of yen	Q1 FY2025	Q1 FY2024
Cash flows from operating activities:		
Income before taxes	¥ 5,817	¥ 37,481
Depreciation and amortization	29,720	33,569
Share of (profit) loss of investments accounted for using the equity method	9,826	17,352
Interest and dividend income	(4,127)	(6,589)
Interest expenses	7,369	7,425
Restructuring costs	2,733	3,533
(Gain) loss on sale of property, plant and equipment, and intangible assets	(131)	(10,135)
(Increase) decrease in trade receivables	61,306	35,473
(Increase) decrease in inventories	(37,499)	(39,931)
Increase (decrease) in trade payables	8,516	3,782
Increase (decrease) in unearned revenue	(1,567)	(2,961)
Increase (decrease) in provisions	1,014	1,268
Others, net	(49,408)	(76,316)
Subtotal	33,569	3,951
Interest and dividends received	6,473	10,643
Interest paid	(5,770)	(7,808)
Income taxes paid	(9,522)	(8,104)
Restructuring costs paid	(752)	(10,940)
Net cash provided by (used in) operating activities	23,998	(12,258)
Cash flows from investing activities:		
Net (increase) decrease in securities	(11,991)	(3,454)
Purchase of property, plant and equipment, and intangible assets	(37,860)	(36,076)
Proceeds from sales of property, plant and equipment, and intangible assets	1,127	12,242
Proceeds from sales of subsidiaries	12,323	—
Payments for sales of subsidiaries	(6,508)	(3,911)
Purchase of other financial assets	(1,141)	(902)
Proceeds from sales and redemption of other financial assets	141	113,633
Others, net	(2,037)	962
Net cash provided by (used in) investing activities	(45,946)	82,494
Cash flows from financing activities:		
Net increase (decrease) in short-term borrowings	16,495	(21,922)
Net increase (decrease) in commercial paper	(24,000)	18,000
Repayments of long-term borrowings	(25,705)	(36,718)
Redemption of bonds	—	(10,000)
Repayments of finance lease liabilities	(4,236)	(4,550)
Cash dividends paid	(9,828)	(4,919)
Cash dividends paid to non-controlling interests	(1,155)	(2,441)
Others, net	(810)	(490)
Net cash provided by (used in) financing activities	(49,239)	(63,040)
Effect of exchange rate changes on cash and cash equivalents	(880)	6,862
Increase (decrease) in cash and cash equivalents	(72,067)	14,058
Cash and cash equivalents at the beginning of the year	209,838	217,449
Net increase (decrease) in cash and cash equivalents resulting from transfer to assets held for sale	4,790	2,751
Cash and cash equivalents at the end of the period	¥ 142,561	¥ 234,258

## (5) Notes to Consolidated Financial Statements

### Framework of Financial Report

The Group's quarterly consolidated financial statements are prepared in accordance with Article 5, Paragraph 2 of the Tokyo Stock Exchange, Inc.'s Standards for the Preparation of Quarterly Financial Statements, applying the omitted disclosures as set forth in Article 5, Paragraph 5 of the Standards for the Preparation of Quarterly Financial Statements.

### Going Concern Assumption

Not applicable.

### Segment Information

#### 1. Reportable Segments

The reportable segments of the Group refer to business units for which separate financial information is available and that are reviewed regularly at the Board of Directors meeting in order to determine the allocation of management resources and evaluate the business performance of each business unit.

The Group divides its operations into business sectors identified by products and services, which manage manufacturing, sales, and research in an integrated manner. Each business sector is responsible for developing comprehensive domestic and overseas strategies with respect to its products and services, and operates its business activities.

Principally in accordance with the business sectors, the Group consists of the five reportable segments based on its products and services: "Agro & Life Solutions," "ICT & Mobility Solutions," "Advanced Medical Solutions," "Essential & Green Materials," and "Sumitomo Pharma."

The reportable segments were changed effective Q3 FY2024; the segment information for Q1 FY2024 has been reclassified to reflect the change.

The major products and services of each reportable segment are as follows:

Reportable Segment	Major Products and Services
Agro & Life Solutions	Crop protection chemicals, fertilizers, agricultural materials, household insecticides, products for control of infectious diseases, feed additives, etc.
ICT & Mobility Solutions	Optical products, semiconductor processing materials, compound semiconductor materials, touch screen sensor panels, high-purity aluminum and alumina, specialty chemicals, additives, engineering plastics, battery materials, etc.
Advanced Medical Solutions	Contract development and manufacturing organization business for advanced small-molecule drug, oligonucleotides, and regenerative medicine and cell therapy products, etc.
Essential & Green Materials	Synthetic resins, raw materials for synthetic fibers, various industrial chemicals, methyl methacrylate products, synthetic resin processed products, industrial alumina, synthetic rubber, etc.
Sumitomo Pharma	Small molecule pharmaceuticals

#### 2. Reportable Segment Information

The accounting methods for each reportable segment are, in principle, identical to those used in the consolidated financial statements. The segment profit or loss is core operating income, which is calculated from operating income after excluding effects from non-recurring factors.

Inter-segment sales revenue is based on market prices.



## First Quarter Fiscal Year 2025

Millions of yen	Agro & Life Solutions	ICT & Mobility Solutions	Advanced Medical Solutions	Essential & Green Materials	Sumitomo Pharma	Total	Others (Note 1)	Adjustments (Note 2)	Consolidated
Sales revenue:									
Sales revenues from external customers	¥ 96,915	¥ 137,412	¥ 9,086	¥ 165,379	¥ 107,362	¥ 516,154	¥ 9,986	¥ —	¥ 526,140
Inter-segment sales revenues	241	1,007	3,700	1,217	640	6,805	12,941	(19,746)	—
Total sales revenue	97,156	138,419	12,786	166,596	108,002	522,959	22,927	(19,746)	526,140
Segment profit (loss) : core operating income (loss)	¥ 2,219	¥ 18,370	¥ (1,024)	¥ (5,463)	¥ 21,003	¥ 35,105	¥ 1,751	¥ (9,175)	¥ 27,681

Note 1: "Others" represents businesses such as supplying electrical power and steam, and providing transport and warehousing, which are not included in reportable segments. Due to the sale of the radiopharmaceutical business and other businesses in FY2024, sales revenue decreased compared to Q1 FY2024,

Note 2: ¥(9,175) million for segment profit (loss) in "Adjustments" includes inter-segment elimination of ¥154 million and corporate expenses of ¥(9,329) million unallocated to each reportable segment. Corporate expenses are mainly research and development expenses for company-wide research, which are not treated as attributable to specific reportable segments.

## First Quarter Fiscal Year 2024

Millions of yen	Agro & Life Solutions	ICT & Mobility Solutions	Advanced Medical Solutions	Essential & Green Materials	Sumitomo Pharma	Total	Others (Note 1)	Adjustments (Note 2)	Consolidated
Sales revenue:									
Sales revenues from external customers	¥ 106,430	¥ 152,673	¥ 13,172	¥ 224,964	¥ 90,598	¥ 587,837	¥ 24,307	¥ —	¥ 612,144
Inter-segment sales revenues	361	1,810	1,692	2,330	10	6,203	17,310	(23,513)	—
Total sales revenue	106,791	154,483	14,864	227,294	90,608	594,040	41,617	(23,513)	612,144
Segment profit (loss) : core operating income (loss)	¥ 4,932	¥ 21,171	¥ 477	¥ (19,608)	¥ 894	¥ 7,866	¥ 4,930	¥ (7,126)	¥ 5,670

Note 1: "Others" represented businesses such as radiopharmaceuticals, supplying electrical power and steam, providing services for the design, engineering, and construction management of chemical plants, and providing transport and warehousing, which were not included in reportable segments.

Note 2: ¥(7,126) million for segment profit (loss) in "Adjustments" included inter-segment elimination of ¥(14) million and corporate expenses of ¥(7,112) million unallocated to each reportable segment. Corporate expenses were mainly research and development expenses for company-wide research, which were not treated as attributable to specific reportable segments.

Adjustments to income before taxes from core operating income were as follows:

Millions of yen	Q1 FY2025		Q1 FY2024	
Core operating income	¥	27,681	¥	5,670
Restructuring costs		(2,733)		(3,533)
Gains on sales of property, plant and equipment, and intangible assets		131		10,135
Others, net		373		(773)
Operating income		25,452		11,499
Finance income		6,681		40,162
Finance expenses		(26,316)		(14,180)
Income before taxes	¥	5,817	¥	37,481

### Material Subsequent Events

(A Company Split (Simplified Absorption-Type Company Split) of the Asian Business of a Subsidiary Company and the Completion of Procedures for its Share Transfer Agreement)

On April 1, 2025, the board of directors of Sumitomo Pharma Co., Ltd., which is a subsidiary of the Company, resolved to execute agreements with Marubeni Global Pharma Corporation, a wholly-owned subsidiary of Marubeni Corporation. The agreements include a share transfer agreement, which stipulates that the Asian business of Sumitomo Pharma's wholly-owned subsidiaries, Sumitomo Pharma (China) Co., Ltd. and Sumitomo Pharma Asia Pacific Pte. Ltd., along with their subsidiaries, will be transferred to a wholly-owned subsidiary to be newly established by Sumitomo Pharma Co., Ltd. (hereinafter, "the New Company") through an absorption-type company split, and that 60% of the shares of the New Company will be transferred to Marubeni Global Pharma Corporation. In addition, procedures for the share transfer agreement were completed as of July 31, and as of that date Sumitomo Pharma (China) Co., Ltd. and Sumitomo Pharma Asia Pacific Pte. Ltd. ceased to be consolidated subsidiaries of Sumitomo Pharma Co., Ltd.

The Company expects to record a gain of approximately ¥45.0 billion in other operating income for Q2 FY2025. However, this amount is an estimate, and it has not yet been confirmed.